- China
- /
- Healthcare Services
- /
- SZSE:301239
Chengdu Bright Eye Hospital Group Third Quarter 2024 Earnings: CN¥0.21 loss per share (vs CN¥0.55 profit in 3Q 2023)
Chengdu Bright Eye Hospital Group (SZSE:301239) Third Quarter 2024 Results
Key Financial Results
- Revenue: CN¥716.3m (down 9.1% from 3Q 2023).
- Net loss: CN¥27.5m (down by 133% from CN¥82.4m profit in 3Q 2023).
- CN¥0.21 loss per share (down from CN¥0.55 profit in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Chengdu Bright Eye Hospital Group Earnings Insights
Looking ahead, revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare industry in China.
Performance of the Chinese Healthcare industry.
The company's shares are down 5.7% from a week ago.
Risk Analysis
It is worth noting though that we have found 2 warning signs for Chengdu Bright Eye Hospital Group that you need to take into consideration.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:301239
Chengdu Bright Eye Hospital Group
A specialized chain medical institution company, engages in the provision of ophthalmic general medical services in China.
Reasonable growth potential with mediocre balance sheet.